Genomic risk classification and whole transcriptome analysis of HR+/HER2- Post-partum breast cancers – A FLEX sub study
Publication: ESMO Breast 2024 Authors: Virginia F. Borges1, Elena Shagisultanova1, Read More
Survival Outcomes for Patients With Invasive Lobular Cancer by MammaPrint: Results From the MINDACT Phase III Trial
Publication: European Journal of Cancer 217 (2025) 115222 Authors: Read More
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King
Publication: International Journal of Molecular Sciences 2025, 26, 491 Read More
FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer
Source: San Antonio Breast Cancer Symposium® Authors: Robert Maganini, Read More
MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Source: San Antonio Breast Cancer Symposium® Authors: Joyce O’Shaughnessy, Read More
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Read More
Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky, VK Read More
Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials
Publication: ESMO Annals of Oncology, Breast cancer, early stage, Read More
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial
Publication: JAMA Network Open. 2024;7(11):e2447530. Authors: Laura J. van Read More
Incorporating Immunotherapy in the Management of Early-Stage Estrogen Receptor-Positive Breast Cancer
Publication: ESMO Open - Volume 9 - Issue 11 Read More
